Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heat therapy for lung tumors: a new option for inoperable patients?

NCT ID NCT00280189

Disease control Sponsor: University of Pittsburgh Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused This study
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at using radiofrequency ablation (RFA) — a procedure that uses heat to destroy tumors — to treat lung cancer or tumors that have spread to the lungs. It is for patients who cannot have surgery due to other health issues. The goal is to see if RFA can control tumors, improve survival, and maintain quality of life. The trial is currently suspended and aims to enroll 72 participants.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
radiofrequency ablation
What this could lead to
If successful, this could offer a less invasive option to control lung tumors and improve quality of life for patients who cannot undergo surgery.
What could go wrong
This trial is suspended and small (72 participants). It is early-stage research, so results may not be conclusive or widely applicable. Risks include procedure-related complications like pain or chest tube drainage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 72 people

The number the study aims to enrol. It can still change while the study runs.

Start date

Sep 2003

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients seeking minimally invasive treatment for pulmonary malignancies.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have stage I or II primary lung cancer and who are felt not to be candidates for resection based upon co-morbid disease or who refuse lung resection. * Have metastatic tumors to the lung, and who meet criteria for metastasectomy but who are felt not to be candidates for resection of all metastases. All metastases should be treatable by RFA alone or in combination with resection. * Have positive tissue diagnosis by previous resection (less than 6 months) or by radiologic biopsy. * Have clinically suspicious disease defined as a new lesion on chest CT or a suspicious PET scan. * Have RF ablation target lesions of 4 centimeters or less in diameter. Exclusion Criteria: * If the lesion is centrally located, less than 3 centimeters from the hilum. * If the target lesion is greater than 4 centimeters in diameter. * If the lesion is metastatic and the primary site is not controlled. * If extra-thoracic metastatic disease is present. * If there are more than 3 tumors in one lung. * If there are greater than 6 metastatic tumors in total (bilateral). * If it is felt that all metastases cannot be treated by RFA alone or in combination with resection. * If the patient is pregnant or nursing at the time of the procedure. * If the patient has malignant pleural effusion. * If the patient is unwilling or unable to provide consent for the procedure. * If the patient is less than 18 years of age (the short form \[SF\]-36 is not designed for patients less than 18 years of age).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metastatic neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC Pulmonary metastases

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hillman Cancer Center

    Pittsburgh, Pennsylvania, 15232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.